Hutch News
Results per Page:
How we measure success matters when evaluating HIV therapies
From Dr. Dan Reeves, Vaccine and Infectious Disease Division
Researchers identify strong T-cell response in first-in-human nanoparticle HIV vaccine
Study result moves scientists closer to developing elusive HIV vaccine
Is the microbiome a springboard or barrier to effective vaccination?
From the Kublin Lab, Vaccine and Infectious Disease Division
Mosaic HIV immunogens boost the breadth of vaccine immune responses
From the Gilbert and McElrath Labs, Vaccine and Infectious Disease Division
On World AIDS Day, a broad view of continuing work
Teams of Fred Hutch scientists test vaccines, treatments, new strategies
Fauci visits Fred Hutch, discusses pandemics, vaccines and scientific misinformation
NIAID director’s determined spirit recognized with honorary Hutch Award
Optimizing antigen design may improve HIV vaccine efforts
From the Pancera, McElrath and Stamatatos labs, Vaccine and Infectious Disease and Clinical Research Divisions
Test of a new 'germline-targeting' HIV vaccine prepares to launch
Vaccine’s unique protein designed to start process of building powerful antibodies against AIDS virus
IAVI and Moderna launch trial of HIV vaccine antigens delivered through mRNA technology
Phase 1 trial aims to build on response seen in proof-of-concept trial
A new path forward: A potential route to effective HIV vaccines
From the Overbaugh Lab, Human Biology Division
AIDS@40: Stories of hope and heroes
The people and the science devoted to stopping HIV
Tip Sheet: Latest research on COVID-19, health disparities, antibodies to parainfluenza, and neuron function
Summaries of recent Fred Hutch research findings and other news
Tip Sheet: New COVID-19 transmission study, returning to school, video of biorepositories — and a new weight loss study
Summaries of recent Fred Hutch research findings and other news
Community engagement in HIV trials guides equity for COVID-19 vaccine studies
New study highlights longstanding barriers to diversity in prior decade of vaccine trials, despite federal guidelines
How do antibodies evolve to kill HIV-infected cells?
From the Overbaugh and Matsen labs, Human Biology and Public Health Sciences Division
HIV vaccine trials are complicated by the availability of PrEP
World AIDS Day 2020: Vaccine researchers still find ways to run trials amid growing use of HIV-prevention drugs
All immunogens are not created equal
From the Stamatatos lab, Vaccine and Infectious Disease Division
Benefits outweigh the social stigma of HIV vaccine trial participation
From the HIV Vaccine Trials Network and the University of Washington
After 20 years, Wakefield retires from HIV Vaccine Trials Network
'He created the DNA of our organization'